Ribociclib succinate is under clinical development by Novartis and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Geode Capital Management LLC reduced its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Free Report) by 11.8% ...

Also sluggish out of the blocks has been Kisqali (ribociclib), Novartis’ competitor to Pfizer's fast-growing breast cancer drug Ibrance (palbociclib), although this has started to come to life ...

The CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib were approved for HR-positive, HER2-negative disease, blocking cyclin-dependent kinases driving tumour growth. Immunotherapies like ...

In 2023, the global breast cancer drug market is projected to be worth USD 10,733.1 million.  Between 2023 and 2033, the demand for breast cancer drugs is expected to expand at a CAGR of 1.1%, ...

Russia and other hostile states have become increasingly brazen in adopting “gray zone” attacks against Europe and the United States, leaving defense officials with a dilemma: How to respond ...

He will be sentenced on Jan. 10, shortly before his inauguration, but is unlikely to face jail time or other penalties. United Statescategory Even before US alcohol warning, younger Americans were ...

New year, new food? Here’s what to know about the top diets of 2025 New year, new food? Here’s what to know about the top diets of 2025 As 2025 arrives, experts break down the trending diets ...